CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language

  • Nat Commun. 2018 Nov 5;9(1):4619. doi: 10.1038/s41467-018-06014-6.
Lot Snijders Blok  1  2  3 Justine Rousseau  4 Joanna Twist  5 Sophie Ehresmann  4 Motoki Takaku  5 Hanka Venselaar  6 Lance H Rodan  7 Catherine B Nowak  7 Jessica Douglas  7 Kathryn J Swoboda  8 Marcie A Steeves  9 Inderneel Sahai  9 Connie T R M Stumpel  10 Alexander P A Stegmann  10 Patricia Wheeler  11 Marcia Willing  12 Elise Fiala  12 Aaina Kochhar  13 William T Gibson  14  15 Ana S A Cohen  14  15 Ruky Agbahovbe  14  15 A Micheil Innes  16 P Y Billie Au  16 Julia Rankin  17 Ilse J Anderson  18 Steven A Skinner  19 Raymond J Louie  19 Hannah E Warren  19 Alexandra Afenjar  20 Boris Keren  21  22 Caroline Nava  21  22  23 Julien Buratti  21 Arnaud Isapof  24 Diana Rodriguez  25 Raymond Lewandowski  26 Jennifer Propst  26 Ton van Essen  27 Murim Choi  28 Sangmoon Lee  28 Jong H Chae  29 Susan Price  30 Rhonda E Schnur  31 Ganka Douglas  31 Ingrid M Wentzensen  31 Christiane Zweier  32 André Reis  32 Martin G Bialer  33 Christine Moore  33 Marije Koopmans  34 Eva H Brilstra  34 Glen R Monroe  34 Koen L I van Gassen  34 Ellen van Binsbergen  34 Ruth Newbury-Ecob  35 Lucy Bownass  35 Ingrid Bader  36 Johannes A Mayr  37 Saskia B Wortmann  37  38  39 Kathy J Jakielski  40 Edythe A Strand  41 Katja Kloth  42 Tatjana Bierhals  42 DDD study John D Roberts  5 Robert M Petrovich  5 Shinichi Machida  43 Hitoshi Kurumizaka  43 Stefan Lelieveld  1 Rolph Pfundt  1 Sandra Jansen  1  3 Pelagia Deriziotis  2 Laurence Faivre  44  45 Julien Thevenon  44  45 Mirna Assoum  44  45 Lawrence Shriberg  46 Tjitske Kleefstra  1  3 Han G Brunner  1  3  10 Paul A Wade  5 Simon E Fisher  47  48 Philippe M Campeau  49  50
Affiliations
  • 1. Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.
  • 2. Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands.
  • 3. Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands.
  • 4. CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
  • 5. National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
  • 6. Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.
  • 7. Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • 8. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • 9. Department of Medical Genetics, Massachusetts General Hospital, Boston, MA 02114, USA.
  • 10. Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands.
  • 11. Nemours Childrens Clinic, Orlando, FL 32827, USA.
  • 12. Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • 13. Valley Children's Hospital, Madera, CA 93636, USA.
  • 14. British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
  • 15. Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • 16. Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • 17. Department of Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust (Heavitree), Exeter, EX2 5DW, UK.
  • 18. Division of Genetics, Department of Medicine, University of Tennessee Medical Center, Knoxville, TN 37920, USA.
  • 19. Greenwood Genetic Center, Greenwood, SC 29646, USA.
  • 20. GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris ; Department of Medical Genetics and Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France.
  • 21. AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.
  • 22. Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France.
  • 23. INSERM, U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, 75013, Paris, France.
  • 24. GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department Child Neurology and Reference Center for Neuromuscular Diseases "Nord/Est/Ile-de-France", FILNEMUS, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France.
  • 25. GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department of Child Neurology and National Reference Center for Neurogenetic Disorders, Armand Trousseau Hospital, GHUEP, AP-HP, INSERM U1141, 75012, Paris, France.
  • 26. Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
  • 27. Clinical Genetics Department, University Medical Center Groningen, Groningen, 9700RB, The Netherlands.
  • 28. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea.
  • 29. Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, 08826, Republic of Korea.
  • 30. Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7HE, UK.
  • 31. GeneDx, Gaithersburg, MD 20877, USA.
  • 32. Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.
  • 33. Northwell Health, Division of Medical Genetics and Genomics, Great Neck, NY 11021, USA.
  • 34. Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands.
  • 35. University Hospitals Bristol, Department of Clinical Genetics, St Michael's Hospital, Bristol, BS2 8EG, UK.
  • 36. Department of Clinical Genetics, University Children's Hospital, Paracelsus Medical University, Salzburg, A-5020, Austria.
  • 37. Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, A-5020, Austria.
  • 38. Institute of Human Genetics, Technische Universität München, Munich, 81675, Germany.
  • 39. Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, 85764, Germany.
  • 40. Communication Sciences and Disorders, Augustana College, Rock Island, IL 61201, USA.
  • 41. Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
  • 42. Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.
  • 43. Waseda University, Tokyo, 169-8050, Japan.
  • 44. Equipe Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, 21070, France.
  • 45. Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France.
  • 46. Waisman Center, Phonology Project, Madison, WI 53705-2280, USA.
  • 47. Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands. [email protected].
  • 48. Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands. [email protected].
  • 49. CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada. [email protected].
  • 50. Sainte-Justine Hospital, University of Montreal, Montreal, QC H3T 1C5, Canada. [email protected].
Abstract

Chromatin remodeling is of crucial importance during brain development. Pathogenic alterations of several chromatin remodeling ATPases have been implicated in neurodevelopmental disorders. We describe an index case with a de novo missense mutation in CHD3, identified during whole genome Sequencing of a cohort of children with rare speech disorders. To gain a comprehensive view of features associated with disruption of this gene, we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs. Experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling. We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.